Highest-materiality recent filing
Cardinal Health Q3 revenue +11% to $60.9B, non-GAAP EPS $3.17 (+35%), raises FY26 outlook
Non-GAAP EPS $3.17, up 35% YoY; GAAP EPS $1.69, down 20% on $184M goodwill impairment in Navista & ION.
Cardinal Health appoints Patricia Hemingway Hall as Board Chair; Kenny retires
Gregory B. Kenny retired as Board Chair and director effective March 20, 2026; no disagreement with company.
Cardinal Health CAO Mary Scherer to retire in Feb 2027; search launched
Mary Scherer, SVP and Chief Accounting Officer, notified Cardinal Health of retirement effective February 2027.
Revenue $65.6B (+19% YoY); GAAP diluted EPS $1.97 (+19%); non-GAAP diluted EPS $2.63 (+36%).
Cardinal Health raises FY2026 non-GAAP EPS outlook to at least $10.00, up from $9.65-$9.85
Raises FY2026 non-GAAP diluted EPS guidance to at least $10.00 from prior range of $9.65-$9.85.
All 12 director nominees elected with >95% support; broker non-votes 21.1M for each.
Cardinal Health Q1 revenue $64B (+22%), non-GAAP EPS $2.55 (+36%); raises FY2026 guidance
Revenue $64B (+22% YoY); GAAP diluted EPS $1.88 (+11%); non-GAAP diluted EPS $2.55 (+36%).
Cardinal Health enters $1B 364-day revolving credit facility expiring Oct 2026
Credit agreement dated October 7, 2025 replaces prior 364-day facility from Oct 2024.
Cardinal Health extends receivables purchase facility term to September 2028
First Amendment to Fifth Amended and Restated Receivables Purchase Agreement dated Sept 30, 2025.
Cardinal Health issues $1B in notes to partially fund Solaris Health acquisition
Issued $600M of 4.500% notes due 2030 and $400M of 5.150% notes due 2035.
Cardinal Health issues $1B notes: $600M at 4.500% due 2030, $400M at 5.150% due 2035
Issued $600M aggregate principal of 4.500% Notes due 2030 and $400M of 5.150% Notes due 2035.
Q4 revenue $60.2B flat YoY (+21% excluding contract expiration); non-GAAP EPS $2.08 (up 13%).
Cardinal Health raises FY25 EPS guidance to $8.15-$8.20; sets FY26 preliminary EPS $9.10-$9.30
Raising FY25 non-GAAP diluted EPS to $8.15-$8.20 (from $8.05-$8.15); 9% growth at midpoint.
Cardinal Health Q3 non-GAAP EPS $2.35, up 13% YoY; raises FY25 EPS guidance to $8.05-$8.15
Revenue $54.9B flat YoY; up 19% ex-customer contract expiration.
Robert Musslewhite, former CEO of Definitive Healthcare, elected to board effective March 7, 2025.
Cardinal Health Q2 non-GAAP EPS $1.93 (+2% YoY); guides FY25 $7.85-8.00, closes GI Alliance deal
Revenue $55.3B (-4% YoY; +16% ex-large customer expiration); GAAP EPS $1.65, non-GAAP EPS $1.93.
Cardinal Health raises FY2025 non-GAAP EPS guidance to high end of $7.75-$7.90 range
Now expects FY2025 non-GAAP EPS toward high end of $7.75 to $7.90, driven by Pharmaceutical & Specialty Solutions strength.
Cardinal Health enters $1.0B term loan for acquisitions of GI Alliance and Advanced Diabetes
$1.0B aggregate term loan facility to pay cash consideration and transaction costs for pending acquisitions of GI Alliance (majority equity) and Advanced Diabetes Supply Group.
Issued $500M of 4.700% Notes due 2026, $750M of 5.000% Notes due 2029, $1B of 5.350% Notes due 2034, and $650M of 5.750% Notes due 2054.
Cardinal Health prices $2.9B multi-tranche senior notes offering (2026-2054)
Issued $500M of 4.700% notes due 2026, $750M of 5.000% notes due 2029, $1,000M of 5.350% notes due 2034, and $650M of 5.750% notes due 2054.
Cardinal Health acquires 71% of GI Alliance for ~$2.8B and ADSG for ~$1.1B
Acquires 71% stake in GI Alliance (gastroenterology MSO) for ~$2.8B cash; remaining ~29% callable at fair value after 3 years.
Cardinal Health shareholders elect 10 directors and approve say-on-pay at 2024 annual meeting
Shareholders elected all 10 nominees to Board of Directors, including Robert W. Azelby and Michelle M. Brennan, with over 192 million votes for each.
Cardinal Health Q1 GAAP EPS $1.70; Non-GAAP EPS $1.88, up 9% YoY; Raises FY25 guidance
Revenue $52.3B, down 4% (up 15% ex-large customer expiration); Pharmaceutical segment profit up 16% to $530M.
Cardinal Health enters $1.0B 364-day credit facility, ups commercial paper program to $3.0B
$1.0B revolving credit facility matures Oct 7, 2025, with optional term-out conversion.
Two Cardinal Health directors not standing for re-election at 2024 annual meeting
Steven K. Barg and Sujatha Chandrasekaran informed company Sept 6 and 8 they will not stand for re-election.
Q4 revenue $59.9B (+12% YoY); GAAP EPS $0.96, non-GAAP EPS $1.84 (+29%).
Cardinal Health Q3 non-GAAP EPS $2.08 (+20% YoY); raises FY24 EPS guidance to $7.30-$7.40
Revenue $54.9B (+9% YoY); GAAP diluted EPS $1.05; non-GAAP diluted EPS $2.08 (+20%).
Cardinal Health recasts segment results under new structure for FY2022-H1 FY2024
New segments: Pharmaceutical & Specialty Solutions and Global Medical Products & Distribution; three smaller ops reported as Other.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On March 7, 2025, the Board of Directors (the “Board”) of Cardinal Health, Inc. (the “Company”) elected Robert W. Musslewhite and Sudhakar Ramakrishna to the Board, effective immediately.
On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.
On September 6, 2024 and September 8, 2024, respectively, Steven K. Barg and Sujatha Chandrasekaran, both members of the Board of Directors (the “Board”) of Cardinal Health, Inc. (the "Company") since 2022, informed the Company that they have decided not to stand for re-election to the Board when their terms expire at the 2024 annual meeting of shareholders.
Max materiality 0.90 · Median 0.68 · Most common event earnings